Early antiretroviral therapy: The role of cohorts

Current Opinion in HIV and AIDS

Volumn 4, Issue 3, 2009, Pages 200-205

  Sabin, Caroline A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antiretroviral therapy; CD4 cell count; HIV infection; When to start treatment

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG POTENCY; EARLY INTERVENTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MORBIDITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; COHORT ANALYSIS; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 67651174417     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32832c06ad     Document Type: Review

References (83)

1. Phillips AN, Gazzard BG, Clumeck N, et al. When should antiretroviral therapy for HIV be started? Br Med J 2007; 334:76-78.
2. Holmberg SD, Palella FJ, Lichtenstein KA, Havlir DV. The case for earlier treatment of HIV infection. Clin Infect Dis 2004; 39:1699-1704. (Pubitemid 39578548)
3. Lane HC, Neaton JD. When to start therapy for HIV infection: a swinging pendulum in search of data. Ann Int Med 2003; 138:680-681.
4. Schechter M. Therapy for early HIV infection: how far back should the pendulum swing? J Infect Dis 2004; 190:1043-1045.
5. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection. 2008 recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 2008; 300:555-570.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, January 29, 2008. pp. 1-128. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf [accessed 21st August 2008].
7. European AIDS Clinical Society (EACS) Guidelines for the Clinical management and treatment of HIV infected adults in Europe. Available at http:// www.eacs.eu/guide/1-Treatment-of-HIV-Infected-Adults.pdf [accessed 21st August 2008].
8. Gazzard BG, on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy (2008). Available at http://www.bhiva.org/files/ file1030835.pdf [accessed 21st August 2008].
9. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naïve participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-1144. This study reports a strong association between the latest CD4 cell count and the risk of several conditions previously thought to be unrelated to HIV infection. As this is a large randomized controlled trial, the analyses are based on well validated and completely ascertained clinical events.
10. Jayasuriya A, Robertson C, Allan PS. Twenty-five years of HIV management. J Roy Soc Med 2007; 100:363-366.
11. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
12. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21:1273-1281. (Pubitemid 46883481)
13. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44:139-147. (Pubitemid 46292215)
14. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120:713-719. (Pubitemid 47176510)
15. Lima VD, Gill VS, Yip B, et al. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. J Infect Dis 2008; 198:51-58. The authors of this study demonstrate a reduced risk of the development of resistance among individuals starting HAART in recent years compared to those starting HAART in earlier years. (Pubitemid 351920289)
16. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a doubleblind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:51-60. (Pubitemid 38122329)
17. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-941.
18. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and nonnucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20:223-231.
19. 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72-77.
20. Keiser O, Taffe P, Zwahlen M, et al. All cause mortality in the Swiss HIV cohort study from 1990 to 2001 in comparison with the Swiss population. AIDS 2004; 18:1835-1843.
21. Bozzette SA, Ake CF, Tam HK, et al. Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47:338-341. (Pubitemid 351619420)
22. Van Sighem A, Danner S, Ghani AC, et al. Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non- HIV-infected individuals. J Acquir Immune Defic Syndr 2005; 40:212-218. (Pubitemid 41395721)
23. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. J Am Med Assoc 2008; 300:51-59. The authors use data from the CASCADE study to show that there remains an excess risk of mortality in those infected with HIV, even after controlling for duration of HIV infection. (Pubitemid 351920404)
24. Dunn D, Woodburn P, Duong T, et al. Current CD4 cell count and the shortterm risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis 2008; 197:398-404. This study provides estimates of the death and AIDS/death rate among individuals of different ages and with difference CD4 cell counts. (Pubitemid 351263421)
25. 3 compared with the general population [Abstract 141]. Presented at 15th conference on retroviruses and opportunistic infections, February 3-6, 2008, Boston, USA.
26. Hessol NA, Kalinowski A, Benning L, et al. Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. Clin Infect Dis 2007; 44:287-294. (Pubitemid 46079997)
27. CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the monotherapy era. AIDS 2004; 18:51-58.
28. + cell counts: a EuroSIDA Study. J Infect Dis 2006; 194: 633-641.
29. Polesel J, Clifford GM, Rickenbach M, et al. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 2008; 22:301-306. Describes a strong association between the CD4 cell count and the risk of non- Hodgkin's lymphoma in the Swiss HIV Cohort Study.
30. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
31. Weber R, Friis-Moller N, Sabin C, et al. HIV and non-HIV related deaths and their relationship to immunodeficiency [Abstract 595]. Presented at 12th conference on retroviruses and opportunistic infections, February 5-8, 2005, Denver, USA.
32. The Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Liver related deaths in persons infected with the human immunodeficiency virus: the DAD study. Arch Int Med 2006; 166:1632-1641.
33. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67.
34. The Data Collection on Adverse Events of Anti-HIV Drugs Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDSdefining malignancies: the D:A:D study. AIDS 2008; 22:2143-2153. This large study reports a strong association between the latest CD4 cell count and both fatal AIDS-defining and non-AIDS-defining malignancies.
35. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22:2409-2418.
36. Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-848. (Pubitemid 351563833)
37. Lazo M, Gange SJ, Wilson TE, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis 2007; 45:1377-1385.
38. 3 or greater. J Acquir Immune Defic Syndr 2007; 45:183-192.
39. Garcia F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr 2004; 36:702-713. (Pubitemid 38685964)
40. CASCADE Collaboration. Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1500 seroconverters. J Acquir Immune Defic Syndr 2003; 32:303-310.
41. + cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44:441-446.
42. Bosch RJ, Bennett K, Collier AC, et al. Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44:268-277. (Pubitemid 46328342)
43. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μL in HIV type 1- infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41:361-372. (Pubitemid 41022115)
44. Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370:407-413. (Pubitemid 47176633)
45. Smith CJ, Sabin CA, Youle MS, et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 2004; 190:1860-1868.
46. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001; 15:2251-2257.
47. Wolbers M, Battegay M, Hirschel B, et al. CD4+ T-cell count increase in HIV- 1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antivir Ther 2007; 12:889-897. (Pubitemid 47492558)
48. Le Moing V, Thiebaut R, Chene G, et al. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. HIV Med 2007; 8:156-163. (Pubitemid 46915686)
49. Girardi E, Sabin CA, d'Arminio Monforte A. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007; 46 (Suppl 1):S3-S8. (Pubitemid 47312320)
50. Wolbers M, Bucher HC, Furrer H, et al. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med 2008; 9:397-405. (Pubitemid 352015643)
51. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. J Am Med Assoc 2001; 286:2560-2567. (Pubitemid 33096807)
52. Lampe FC, Gatell JM, Staszewski S, et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy. A multicohort analysis, 1996 to 2002. Arch Int Med 2006; 166:521-528.
53. European Collaborative Study. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 2007; 44:1647-1656. (Pubitemid 46871514)
54. Collazos J, Knobel H, Casado JL. CD4 count and viral load time-courses in patients treated with highly active antiretroviral therapy and association with the CDC staging system. HIV Med 2006; 7:504-513. (Pubitemid 44742350)
55. Robbins GK, Daniels B, Zheng H, et al. Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr 2007; 44:30-37. (Pubitemid 46052217)
56. Braithwaite RS, Kozal MJ, Chang CCH, et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS 2007; 21:1579-1589.
57. Kuyper LM, Wood E, Montaner JSG, et al. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-infected patients in a population-based cohort. J Acquir Immune Defic Syndr 2004; 37:1470-1476. (Pubitemid 39602337)
58. Ahdieh-Grant L, Yamashita TE, Phair JP, et al. When to initiate highly active antiretroviral therapy: a cohort approach. Am J Epidemiol 2003; 157:738-746. (Pubitemid 36423087)
59. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. J Am Med Assoc 2001; 279:450-454.
60. Chan KC, Yip B, Hogg RS, et al. Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States. AIDS 2002; 16:1693-1695. (Pubitemid 34921119)
61. Kaplan JE, Hanson DL, Cohn DL, et al. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350cells/microL. Clin Infect Dis 2003; 37:951-958.
62. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129. (Pubitemid 34786200)
63. Jacobson LP, Li R, Phair J, et al. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression. Am J Epidemiol 2002; 155:760-770. (Pubitemid 34297657)
64. 3. Antiviral Therapy 2007; 12:941-947.
65. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. J Am Med Assoc 2001; 286:2568-2577. (Pubitemid 33096808)
66. The Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1- infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21:1185-1197.
67. 3: disease progression, treatment durability, and drug toxicity. Clin Infect Dis 2003; 36:812-815.
68. Sterling TR, Chaisson RE, Keruly J, Moore RD. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J Infect Dis 2003; 188:1659-1665. (Pubitemid 38010676)
69. Palella FJ, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Int Med 2003; 138:620-626. (Pubitemid 38124652)
70. Bonnet F, Thiebaut R, Chene G, et al. Determinants of clinical progression in antiretroviral-naïve HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. HIV Med 2005; 6:198-205.
71. Wang C, Vlahov D, Galai N, et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004; 190:1046-1054. (Pubitemid 39186789)
72. Moore RD, Gebo KA, Lucas GM, Keruly JC. Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin Infect Dis 2008; 47:1102-1104. Demonstrates that HAART may have an impact on several serious non-AIDS events if initiated at CD4 cell counts of less than 350 cells/μl.
73. Braithwaite RS, Roberts MS, Chang CCH, et al. Influence of alternative thresholds for initiating HIV treatment on quality adjusted life expectancy: a decision model. Ann Int Med 2007; 148:178-185.
74. Cole SR, Li R, Anastos K, et al. Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. Stat Med 2004; 23:3351-3363. (Pubitemid 39462092)
75. Cole SR, Hernán MA, Anastos K, et al. Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. Am J Epidemiol 2007; 166:219-227. This important study demonstrates the use of appropriate statistical methods (including methods to deal with time-varying confounding as well as changes in viral load detection limits over time) to assess the effect of HAART on virological outcomes when initiated at different CD4 cell count levels. (Pubitemid 47227283)
76. Jaen A, Esteve A, Miro JM, et al. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47:212-220. The authors of this study use appropriate statistical methods to adjust for lead-time bias and the unseen sample of rapid progressors and conclude that the optimal time to start HAART is before the CD4 count has fallen below 350 cells/μl. (Pubitemid 351172189)
77. 3 is associated with improved survival [Abstract H-896b]. 48th ICAAC/46th IDSA, Washington DC, October 2008. Although only currently available as an abstract, this analysis is notable for using appropriate statistical methods to attempt to deal with several sources of bias that may be present in cohort studies.
78. Horne R, Buick D, Fisher M, et al. Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with nonadherence to HAART. Int J STD AIDS 2004; 15:38-44. (Pubitemid 38096128)
79. Horne R, Cooper V, Gellaitry G, et al. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence. The utility of the necessity-concerns framework. J Acquir Immune Defic Syndr 2007; 45:334-341. (Pubitemid 47012382)
80. Nilsson Schonnesson L, Williams ML, Ross MW, et al. Three types of adherence to HIV antiretroviral therapy and their association with AIDS diagnosis, medication side-effects, beliefs about antiretroviral therapy, and beliefs about HIV disease. Int J STD AIDS 2007; 18:369-373.
81. Cairns G. When to start therapy? The patients viewpoint. Presented at HIV9.
82. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. Br Med J. doi: 10.1136/bmj.38875.675486.55.
83. Walker AS, Ford D, Mulenga V, et al. Adherence to both cotrimoxazole and placebo is associated with improved survival among HIV-infected Zambian children. AIDS Behav 2008. doi: 10.1007/s10461-008-9382-4. This study provides a very eloquent demonstration that variations in adherence to placebo in a study can have impacts on treatment outcomes that are comparable to the effects apparently attributable to pre-HAART CD4 cell count differences that are reported from cohort studies.